Recombinant birch pollen allergoid - Allergopharma

Drug Profile

Recombinant birch pollen allergoid - Allergopharma

Alternative Names: Bet v 1 - Allergopharma; Betv1; Recombinant birch pollen

Latest Information Update: 05 Apr 2013

Price : $50

At a glance

  • Originator Allergopharma
  • Class Allergens; Antiallergics; Tree pollen allergy immunotherapies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • No development reported Seasonal allergic rhinitis

Most Recent Events

  • 05 Apr 2013 No development reported - Phase-III for Seasonal allergic rhinitis in Germany (Parenteral)
  • 24 Aug 2010 Phase III development is ongoing in Germany
  • 01 Jun 2009 Allergopharma completes a Phase-III trial in Seasonal allergic rhinitis in Germany (NCT00309062)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top